About Paul Kleutghen
Articles by Paul Kleutghen
BCMA Loss After Multiple Myeloma CAR T Infusion and What it Means for Del17 PatientsJun 30, 2021
New CAR T Therapy Shows 100% Overall Response Rate in Relapsed and Refractory Multiple MyelomaJun 14, 2021
Salvage Therapy for Aggressive Types of Multiple Myeloma: Plasma Cell Leukemia and Extramedullary MyelomaJun 04, 2021
Chemo Brain for the Multiple Myeloma PatientMay 21, 2021
Mobilizing Stem Cells from Myeloma Patients prior to Stem Cell TransplantMay 13, 2021
Venetoclax as a Treatment Option for Relapsed Plasma Cell Leukemia PatientsApr 08, 2021
Helpful Resources for Multiple Myeloma Patients Considering Stem Cell TransplantsMar 22, 2021
What About Autologous Stem Cell Transplant for Older Multiple Myeloma Patients?Feb 25, 2021
A Prior Cancer Diagnosis and Later Development of Multiple MyelomaFeb 17, 2021
Interfering with a Specific Gene (IRF4) to Treat Multiple MyelomaFeb 04, 2021
TMA, a Rare Complication of Stem Cell TransplantsJan 28, 2021
COVID-19 Isolation Precautions for Immunocompromised PatientsDec 03, 2020
Predicting Response to Carfilzomib (Kyprolis) in Multiple MyelomaNov 16, 2020
Statins Reduce Mortality in Multiple Myeloma PatientsOct 14, 2020
A Pretty Flower Toxic to Multiple MyelomaOct 13, 2020
Vitamin D Levels Impact Myeloma Patient Outcomes After TransplantAug 10, 2020
High Risk Myeloma and the Benefit of Tandem Transplants with Long-Term Revlimid MaintenanceJul 09, 2020
CelMoDs: Not Just Another Immmuno-modulatory DrugJul 02, 2020
Another Bi-Specific Antibody for Multiple Myeloma TreatmentJul 01, 2020
Good News: Long Term Follow Up of Revlimid/Velcade/Dex UseJun 28, 2020
Improved Understanding of Chronic Graft Versus Host DiseaseMay 14, 2020
Vitamin D Levels Play a Role in COVID-19 Mortality RatesMay 11, 2020
Vitamin D Deficiency Affects Overall Survival of Multiple Myeloma PatientsMay 08, 2020
El Mieloma múltiple, trasplantes de células madre y ... La “culebrilla”Mar 05, 2020
